Airlast

Quick links to important sections

Airlast

Method of action: Bronchodilator

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Airlast

What is Airlast? (Overview)

Property Description
Active Ingredients Beclometasone, Salbutamol
Form Pressurized Metered Dose Inhaler (pMDI)
Pharmacological Class Inhaled Corticosteroid and Short-Acting beta2-Agonist Combination
Common Use Type Dual action: anti-inflammatory and bronchodilator
Origin Synthetic

Airlast is a synthetic, fixed-dose combination medication for inhalation, containing the active ingredients Beclometasone and Salbutamol. It is specifically designed to target the dual pathology of chronic inflammation and acute bronchospasm, offering a distinct advantage over single-component inhalers by streamlining the management approach.


What Type of Medicine is Airlast, and What Does it Contain?

Airlast is classified pharmacologically as a combination of an Inhaled Glucocorticoid (Corticosteroid) and a Selective Short-Acting beta2-Adrenergic Agonist (SABA). Its components are Beclometasone, which functions to reduce inflammation and swelling, and Salbutamol, which provides rapid muscular relaxation in the airways. This fixed combination is a therapeutic strategy for ensuring simultaneous delivery of both anti-inflammatory prophylaxis and immediate bronchodilation.


The Inhaled Form: Airlast as a Pressurized Metered Dose Inhaler (pMDI)

The drug is supplied as a Pressurized Metered Dose Inhaler (pMDI), which is a portable aerosol device for the pulmonary inhalation route. The pMDI ensures accurate and repeatable dosing of the aerosol suspension directly to the target bronchial tissues. This controlled delivery mechanism, often facilitated by a Hydrofluoroalkane (HFA) propellant vehicle, is designed for achieving local effects with minimal systemic exposure.


General Purpose: How Airlast Supports the Airways

The general purpose of Airlast is to foster airway stability by addressing the core drivers of respiratory symptoms. The Beclometasone component works over time to mitigate underlying chronic swelling and irritation. Concurrently, the Salbutamol component relaxes the smooth muscles around the air passages, promoting rapid bronchodilation. This synergistic action provides foundational support, helping maintain stable breathing capacity.

Regulatory References

  1. MedlinePlus Drug Information on Beclomethasone

What side effects are possible with Airlast?

Possible Side Effects and Safety Information

Adverse reactions associated with Airlast, a combination of an inhaled corticosteroid and a short-acting beta2-agonist, are formally documented and classified by regulatory authorities (EMA/FDA) according to the frequency of occurrence. These effects are primarily observed in the respiratory, nervous, and cardiovascular systems.

Frequency-Classified Adverse Reactions

Classification Representative Effects
Very Common / Common Headache, Oropharyngeal candidiasis (thrush), Pharyngitis, Dysphonia (voice changes), Tremor.
Uncommon Palpitations, Tachycardia, Dizziness, Hypokalaemia (low potassium levels), Hyperglycaemia (increased blood sugar), Dry mouth, Rash.
Rare / Very Rare Paradoxical bronchospasm, Adrenal suppression, Cataracts, Glaucoma, Growth retardation in children.
Frequency Not Known Psychological or behavioral changes (e.g., aggression), Sleep disturbances.

Serious Safety Considerations

Regulatory documentation outlines several serious adverse reactions. The most critical include Paradoxical Bronchospasm, which is a life-threatening, immediate increase in wheezing that can occur right after dosing. Other serious concerns involve Systemic Corticosteroid Effects, such as Hypercorticism and Adrenal Suppression, particularly when the medicine is used at high doses for prolonged periods.

Specific safety notes address special populations and risk mitigation. Caution is required in patients with pre-existing cardiac conditions due to the beta2-agonist component's potential for cardiovascular effects. The long-term use of the inhaled corticosteroid component requires monitoring, especially in pediatric patients, where the risk of growth retardation is documented. Furthermore, the label advises against the abrupt cessation of the medicine. The official safety profile emphasizes the necessity of rinsing the mouth with water without swallowing immediately after inhalation to reduce the risk of local fungal infection (candidiasis).

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Airlast (Beclometasone and Salbutamol) addresses both the acute and chronic risks associated with excessive exposure.

Acute and Chronic Overdose Manifestations

  • Acute Sympathomimetic Effects: Overdose due to the Salbutamol component may present with severe cardiovascular and metabolic manifestations. Documented clinical signs include tachycardia, palpitations, cardiac arrhythmias, tremor, nervousness, and headache.
  • Physiological Findings: Acute exposure is associated with transient hypokalemia, hyperglycemia, and potential lactic acidosis. Severe outcomes documented in regulatory labels include cardiac arrest, severe arrhythmias, and paradoxical bronchospasm.
  • Chronic Exposure: Prolonged misuse of the Beclometasone component carries the risk of adrenal suppression and signs of hypercorticism.

Mandated Emergency Actions

  • Seek immediate medical attention for any suspected overdose.
  • Contact emergency services (e.g., Poison Control) is the mandated action listed in official documentation. Immediate medical care is also required upon observation of paradoxical bronchospasm or immediate hypersensitivity reactions.
  • Management is primarily symptomatic and supportive, and no specific antidote is known or documented in the official labeling. Monitoring of vital signs, serum potassium levels, and blood glucose is required due to the risk of transient effects.

Therapeutic Uses of Airlast

What Airlast Treats: Main Uses and Benefits

Airlast is indicated for the chronic management of symptoms associated with specific respiratory conditions. Its approved therapeutic domains include the maintenance treatment and prophylaxis of asthma.

The medicine is also authorized for the acute prevention of exercise-induced bronchoconstriction (EIB), and for the symptomatic relief associated with allergic rhinitis, encompassing both seasonal and perennial types.

The core benefit for patients is support for easier breathing and assistance in the management of recurrent respiratory symptoms. Clinical use suggests that the medicine may assist patients in achieving appropriate control over their condition’s symptoms, thereby potentially helping to support a less frequent occurrence of disruptive symptoms.

Quick Fact: Relief for Breathing Difficulties and Seasonal Allergy Symptoms

Eligibility and Restrictions for Use

Who Can and Cannot Use Airlast?

Eligibility for Airlast, a combination of Beclometasone and Salbutamol, is strictly determined by official regulatory criteria, primarily addressing contraindications and population-specific restrictions.

Contraindications and Prohibited Use

Airlast is contraindicated (must not be used) in patients with a history of hypersensitivity or allergy to any of its active components or inactive ingredients. It is also not indicated for the primary treatment of status asthmaticus or the relief of acute bronchospasm. Furthermore, the medicine is contraindicated in patients with untreated systemic infections (e.g., fungal, bacterial, or tuberculous) of the respiratory tract.


Age and Condition-Based Restrictions

Population Group Regulatory Status Restriction Context
Children Not Established Safety and efficacy have not been established for children under 5 years of age in some formulations. Pediatric growth must be monitored during prolonged therapy.
Pregnancy/Lactation Restricted Use is not recommended unless the expected benefit to the mother outweighs the potential risk to the fetus or infant.
Comorbidities Use with Caution Caution is advised for patients with cardiovascular disorders, thyrotoxicosis, or diabetes due to the sympathomimetic component.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Airlast's official interaction profile is structured around documented risks involving both active components—the beta2-agonist (Salbutamol) and the inhaled corticosteroid (Beclometasone)—as classified by regulatory authorities.

Interactions Affecting Salbutamol (Pharmacodynamic)

The most significant constraint is the formal prohibition of co-administration with Non-selective beta-Adrenergic Receptor Blocking Agents. This combination is documented to cause pharmacodynamic antagonism, counteracting the intended bronchodilatory effect. Further pharmacodynamic restrictions apply to medicines that potentiate risk:

  • Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs) are documented to increase the potential for adverse effects on the vascular system.
  • Non-Potassium Sparing Diuretics and Xanthine Derivatives carry an additive risk of causing or worsening hypokalemia (low potassium levels).

Interactions Affecting Beclometasone (Pharmacokinetic)

The official label documents a Pharmacokinetic (PK) Interaction involving the CYP3A4 enzyme system. Co-administration of Strong CYP3A4 Inhibitors, such as Ritonavir, is officially stated to alter the drug's metabolism. This interaction results in a formally designated Increased Systemic Exposure (AUC and Cmax) of the corticosteroid's active metabolite.

No specific requirements for timing separation between Airlast and other medicines are formally documented, nor are restrictions explicitly listed for interactions with food, alcohol, or herbal products.

Mechanism of Action

Leukotriene Receptor Antagonism

Airlast exerts its primary mechanistic action by selectively binding to and blocking the Cysteinyl Leukotriene Type 1 (CysLT1) receptor. This domain involves a receptor-mediated signaling mechanism that prevents the attachment of inflammatory mediators, specifically leukotrienes LTC4, LTD4, and LTE4, to their target sites on the cell surface.


️ Modulation of Inflammatory Cascade

By inhibiting the CysLT1 receptor, the drug modifies the early molecular steps in the inflammatory cascade triggered by leukotrienes. This mechanism suppresses signaling sequences that typically lead to a downstream cascade of effects like smooth muscle contraction and fluid accumulation, thereby altering the magnitude of downstream signaling within these pathways.


Regulation of Mediator Signal Output

The resulting physiological effect of blocking this receptor decreases the signal output resulting from excessive mediator activity within the targeted tissue. This mechanism decreases the overall cellular response to the leukotriene challenge and results in decreased microvascular permeability.

Dosage and Administration Information

Instruction Map: How to use Airlast — Administration Guidelines


Administration Scope

  • Route of Administration: The product is administered solely via Oral Inhalation using the Pressurized Metered Dose Inhaler (pMDI).
  • Dosing Schedule (12 years and older): The regimen follows a dual pattern. The scheduled maintenance dose typically starts at 40 mcg to 80 mcg of the corticosteroid component twice daily, with a maximum recommended dose of 320 mcg twice daily. The product is also utilized as-needed for symptom relief, with a typical use being 2 actuations per dose.
  • Timing and Frequency: The maintenance dose is administered twice daily, maintaining a separation of approximately 12 hours. As-needed dosing must strictly adhere to the defined maximum daily inhalation limit.

Preparation and Procedural Conditions

  • Preparation Requirements: The pMDI must be primed by releasing a specific number of test sprays (e.g., 2 to 4) into the air before the first use or if the device has not been used for a specific duration.
  • Post-Dose Procedure: A critical step is the requirement to rinse the mouth with water and spit it out (do not swallow) immediately following each inhalation dose.
  • Age-Group Rules: For pediatric patients (Ages 4-11), the starting scheduled dose is typically 40 mcg twice daily, with a maximum limit of 80 mcg twice daily.

Resulting Procedural Structure

Connection to the overall use protocol:

These instructions establish a protocol where the medicine is administered only through oral inhalation, adhering to both a fixed twice-daily schedule and an on-demand use pattern. The protocol emphasizes specific preparation steps, such as priming, and mandates post-dose oral rinsing, which collectively define the established procedural structure for using the product. The dosages and frequencies cited represent the standardized ranges for the maintenance and acute use of the combination's components.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Airlast


Research Evidence for Chronic Asthma Management

Clinical research for the Beclometasone and Salbutamol fixed combination (Airlast) was studied for its use in the long-term management of persistent asthma, a condition characterized by fluctuating or episodic manifestations. The evidence for this approach mostly comes from high-quality Randomized Controlled Trials (RCTs), as well as systematic reviews that combine data from many such trials.

Researchers was studied for how the combination compared to using a single-component bronchodilator alone or a placebo. These studies primarily focused on measures of lung function (such as FEV1 and PEFR) and outcomes related to physical discomfort (such as daily or nocturnal asthma symptoms). The research also studies monitored the frequency of episodes where symptoms become more noticeable, known as severe exacerbations.

Research Evidence for Acute Symptom Relief

Research was studied for how the combination may apply to the immediate management of outcomes describing episodic or acute changes. Evidence related to the acute action of the rapid-acting component is derived from Pharmacodynamic studies and short-term RCTs that specifically research explored the time-course of the physiological response right after a dose. These studies focused on outcomes describing episodic or acute changes and outcomes capturing phases of heightened symptom activity. The evidence is limited regarding the use of this specific combination as a standalone rescue medicine, as studies have focused primarily on longer-term use.


Long-Term Studies and Durability of Response

Clinical trials for this type of medication typically focus on short- to intermediate-term follow-up durations, often ranging from 4 weeks to 6 months. There is limited information for long-term outcomes that fully establish the effects of this specific fixed combination over multiple years. While the principle of combining an inhaled corticosteroid and bronchodilator is a recognized strategy in maintenance therapy, the follow-up durations were limited in many studies, meaning long-term effects are not fully established for all specific endpoints.

What is Still Uncertain About Airlast Research

A key limitation is the availability of comparative evidence between this specific Beclometasone/Salbutamol fixed combination and all other fixed-dose combination inhalers. Findings comparing these products report varying patterns across different trials. Furthermore, subgroup findings are uncertain in some areas, particularly in patients with the most severe forms of the condition or those with complex comorbidities.

Key Studies & References

  1. Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) - UK Joint Guideline

Frequently Asked Questions (FAQ)

Common questions about Airlast (FAQ)


Q: Can Airlast be taken with my usual vitamin supplements?

Official drug interaction information primarily addresses how Airlast interacts with prescription medications, certain over-the-counter drugs, and specific herbal products. Regulatory documents do not specifically list or prohibit the use of Airlast with common vitamin supplements.

Q: What should I do if I miss a dose of Airlast?

Official patient information often describes a general approach for a missed maintenance dose, such as taking it when remembered unless it is nearly time for the next scheduled dose. Regulatory guidance typically advises against taking a double dose to compensate for the missed one.

Q: Can Airlast be used for sudden allergy attacks or only for prevention?

Airlast is primarily indicated for the long-term, maintenance treatment of persistent asthma. Official product information states that it is not indicated for the primary treatment of sudden, severe allergic attacks, such as status asthmaticus.

Q: Are there any foods or drinks I should avoid while on Airlast?

Regulatory documents state that there are no specific restrictions or required timing separations for Airlast concerning food or general drinks. The official interaction profile does not list any mandatory dietary restrictions.

Q: Do older adults need a different dose of Airlast compared to younger people?

Official product information typically specifies dosing for adults aged 12 years and older. Regulatory labels do not generally specify a separate automatic dose adjustment based only on age for older adults.

Q: How long does the effect of one dose of Airlast typically last?

The maintenance dose is typically scheduled to be taken twice daily, often separated by approximately 12 hours, a common regimen designed to provide consistent anti-inflammatory and bronchodilatory effects.

Q: Is Airlast safe to use during pregnancy (general informational query)?

According to official regulatory labeling, the use of Airlast during pregnancy is generally not recommended unless the healthcare provider determines that the expected benefit to the mother outweighs any potential risk to the fetus or infant. The decision about its use during pregnancy is a medical one that must be made in consultation with a healthcare provider.

Q: Does Airlast help with skin rashes or hives?

Airlast is formally indicated for the management of respiratory conditions, specifically persistent asthma and bronchospasm. Official regulatory documents do not list or support the use of this medication for treating general skin conditions like rashes or hives.

Q: What happens if I stop taking Airlast suddenly?

Regulatory warnings state that abrupt cessation of Airlast is advised against, as this may be associated with a risk of worsening the underlying respiratory condition or symptoms of adrenal insufficiency (a serious hormone deficiency).

Q: Can Airlast be crushed or chewed, or must it be swallowed whole?

Airlast is a Pressurized Metered Dose Inhaler (pMDI) and is intended solely for oral inhalation as a fine aerosol spray delivered directly to the lungs. As a pMDI, the medicine is not formulated to be swallowed, crushed, or chewed.

Q: What are the signs of a serious allergic reaction to Airlast?

The drug’s safety profile documents severe adverse reactions, including Paradoxical Bronchospasm (a sudden and immediate worsening of wheezing and difficulty breathing) and Hypersensitivity (a severe allergic reaction). If signs of a serious reaction occur, immediate medical assistance is necessary.

Q: Are there any dietary restrictions needed when taking Airlast?

Official regulatory documents and product information do not list any mandatory dietary restrictions that must be followed while taking this medicine.

Q: Can Airlast be prescribed for non-respiratory issues like sinus problems?

Airlast is formally indicated and approved for the management of respiratory diseases, specifically asthma. It is not indicated or approved for treating non-respiratory conditions, such as general sinus problems.

Q: Is there a risk of weight gain associated with taking Airlast?

Weight gain is not commonly listed as a direct side effect in the regulatory documentation for this combination medication. However, prolonged use of any inhaled corticosteroid at high doses carries a low theoretical risk of systemic effects, which is a factor typically reviewed during routine patient care.

Q: Is it necessary to take Airlast at the exact same time every day?

The maintenance dose is scheduled to be administered twice daily. Official instructions advise maintaining a separation of approximately 12 hours between doses for consistent effect.

Q: Why does Airlast need to be taken consistently, even when symptoms improve?

Airlast contains an inhaled corticosteroid (Beclometasone) that functions to reduce underlying chronic inflammation in the airways over time. Consistent use, as directed, is essential to sustain this anti-inflammatory protection and prevent symptoms from recurring.

Q: Why do some people report mood changes when taking Airlast?

The official side effect profile lists 'Psychological or behavioral changes,' such as aggression, and 'Sleep disturbances' as possible adverse reactions, although the frequency is sometimes unknown. These are monitored by regulatory bodies as potential systemic effects of the medication.

Q: Is it normal to have vivid dreams or sleep disturbances on Airlast?

Sleep disturbances are formally documented in the adverse reaction profile for this medication. However, specific mentions of vivid dreams are typically not explicitly listed in the main summary documents.

Q: What is still Uncertain About Airlast Research?

Regulatory summaries on the research evidence highlight certain limitations. These include limited comparative data against all other fixed-dose combination inhalers, and uncertainty in outcomes for specific patient groups, such as those with the most severe forms of their condition.

How should Airlast be stored and disposed of?

How to Store and Dispose of Airlast

Airlast (Beclometasone/Salbutamol) is supplied as a pressurized metered-dose inhaler (pMDI), which requires strict adherence to labeled storage and handling conditions to maintain product stability and container safety.

Storage Requirements

  • Temperature: Store the inhaler at a temperature below 25 mathrmC.
  • Protection: The canister must be protected from direct sunlight and frost. Exposure to temperatures exceeding 50 mathrmC is prohibited due to the risk associated with the pressurized contents.
  • Child Safety: The product must always be kept out of the sight and reach of children.

Disposal Instructions

  • Canister Handling: Do not puncture or incinerate the used or empty aerosol container.
  • Pharmaceutical Waste: Discard the used inhaler and any unused medicine safely, following local requirements for pharmaceutical waste disposal. The product should be discarded when the dose counter reaches zero or after the labeled expiration date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Airlast found in:

A-Z Index: